Core Viewpoint - Guangdong Jushi Chemical Co., Ltd. (stock code: 688669) has been penalized by the China Securities Regulatory Commission (CSRC) for violations related to information disclosure, specifically for inflating revenue, costs, and profits through fictitious trade activities [2][6]. Group 1: Violations and Penalties - The CSRC found that Jushi Chemical and its subsidiaries engaged in fictitious trade activities, including controlling companies that conducted trades without actual goods, resulting in inflated revenue of approximately 156.81 million yuan, inflated costs of about 158.47 million yuan, and a reduced profit of around 1.66 million yuan, which represented 8.32%, 8.51%, and 6.81% of total revenue, costs, and profit respectively for the first half of 2023 [2][6]. - The CSRC has ordered Jushi Chemical and its responsible personnel to rectify the situation, issued warnings, and imposed fines [2][6]. Group 2: Legal Implications for Investors - Investors who suffered losses due to Jushi Chemical's actions can seek civil compensation, which includes investment differences, commissions, and stamp duties, as per the Civil Code and Securities Law [3][7]. - A lawyer has initiated a campaign to collect claims from investors who purchased Jushi Chemical's securities between August 29, 2023, and November 21, 2025, and either sold or continued to hold them after November 22, 2025 [8][7]. Group 3: Claim Registration Requirements - Investors wishing to register claims must provide specific documents, including a copy of their ID, original securities account confirmation, and transaction records stamped by their brokerage [9].

Core Viewpoint - The company, Jushi Chemical, has been found guilty of financial fraud, inflating its revenue and costs in its 2023 semi-annual report, leading to significant penalties and potential investor claims [1][3]. Group 1: Financial Fraud Details - Jushi Chemical inflated its revenue by 157 million yuan and its operating costs by 158 million yuan in the first half of 2023 [1][3]. - The company utilized three main methods for inflating its financial figures, including engaging in fictitious trades with controlled companies, manipulating trade chains, and reporting sales of goods that were never actually shipped [5]. - The inflated figures represented 8.32% of total revenue, 8.51% of total costs, and resulted in a profit reduction of 166.29 million yuan, accounting for 6.81% of total profit [5]. Group 2: Investor Claims - Investors who purchased Jushi Chemical shares between August 29, 2023, and November 21, 2025, and suffered losses are eligible to file claims [3]. - The formal penalties serve as strong evidence for investors seeking compensation for their losses due to the company's fraudulent activities [3]. Group 3: Company Performance Outlook - Jushi Chemical has been experiencing deteriorating business conditions, with projections indicating a significant decline in performance for 2024 and 2025 [7]. - The company is expected to report a net loss of between 90 million and 120 million yuan for the year 2025, marking its second consecutive year of losses [7]. - The decline in revenue is attributed to a significant drop in the liquefied petroleum gas business, heavily influenced by fluctuations in international crude oil prices [7].

Core Viewpoint - The administrative penalty decision reveals that Jushi Chemical and its subsidiaries inflated revenue by 157 million yuan through false trading practices, highlighting investor protection issues [1][2]. Group 1: Investor Compensation Conditions - Jushi Chemical announced on February 3, 2026, that it received an administrative penalty from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission, confirming the inflation of revenue, costs, and profits through false trading [2][9]. - Investors must meet specific conditions to qualify for compensation: they must have purchased shares after the company engaged in false statements and held them until the misconduct was publicly revealed or corrected [3][10]. - The period for eligible investors to claim compensation is from August 29, 2023, to November 21, 2025, with losses incurred after November 22, 2025, also qualifying [4][11]. Group 2: Revenue Inflation Details - The administrative penalty detailed three methods used by Jushi Chemical to inflate revenue: 1. Engaging in false trades with four trading companies controlled by its subsidiary, resulting in an inflated revenue of 86.55 million yuan and a profit reduction of 1.687 million yuan [4][11]. 2. Involvement in third-party trade chains, inflating both revenue and costs by 52.23 million yuan [4][11]. 3. Sales of isooctane without actual shipment, inflating revenue by 18.02 million yuan [4][11]. - Overall, the company inflated its revenue by 157 million yuan, costs by 158 million yuan, and reduced profits by 1.6629 million yuan, representing 8.32%, 8.51%, and 6.81% of total revenue, costs, and profit respectively for the first half of 2023 [4][11]. Group 3: Company Performance - Jushi Chemical, primarily engaged in the research, production, and sales of new chemical materials, has faced deteriorating operational conditions, with significant performance declines expected in 2024 [5][13]. - For 2025, the company anticipates a net loss attributable to shareholders ranging from 90 million to 120 million yuan, marking its second consecutive year of losses [6][13]. - The decline in revenue and increased losses in the liquefied petroleum gas business are attributed to fluctuations in international crude oil prices [7][13].

宇新股份：快速成长的碳四深加工龙头国内LPG 深加工龙头。公司产品矩阵持续完善，主要产品包括 异辛烷、MTBE、乙酸仲丁酯、顺酐、丁酮、乙酸乙酯等。董事长研发出身，重视创新引领企业发展， 多管理层亦拥有技术背景，持股共享公司发展成果。公司营收稳健增长，受行业景气度影响，短期盈利 承压。 红海沉浮，创新引领，细分开拓局部蓝海 区位筑基，研发赋能，构筑成本护城河 公司凭借优越地理区位与卓越研发实力双重引擎，实现领先盈利水平。原料端靠近上游炼厂，销售端靠 近下游终端消费市场；持续研发投入为生产端带来长足发展优势，全组分利用的同时，打造物料与能源 的多重循环生产系统，高原子利用效率与经济性并行。 投资建议 作为国内LPG 深加工龙头，预计公司2025 年-2027 年归母净利润为-0.39 亿元、4.02 亿元和7.60 亿元， 2026 年级2027 年对应2026 年1 月28 日收盘价PE 为11.4X、6.0X，首次覆盖，给予"买入"评级。 风险提示 1、国际油价大幅波动；2、地缘政治风险；3、国际市场运营带来的风险；4、自然灾害、恶劣天气等自 然因素带来的风险；5、盈利预测假设不成立或不及预期的风险。 经过 ...

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [10]. Core Insights - The company is positioned as a leading player in the LPG deep processing sector in South China, leveraging its advantageous geographical location and innovative development to achieve rapid growth [3][6]. - The product matrix of the company is continuously improving, with key products including isooctane, MTBE, and butanediol, among others. The management team, with a strong technical background, emphasizes innovation to drive the company's growth [6][20]. - The company is actively expanding its market presence through chain extension, industrial collaboration, and overseas demand expansion, aiming to create new growth engines in a competitive market [3][7]. Summary by Sections Company Overview - The company, established in October 2009 and listed in 2020, focuses on the research and production of organic chemical products using LPG as raw material. Its main production bases are located in the Huizhou Daya Bay petrochemical area [20][23]. Product and Market Position - The company has achieved comprehensive utilization of LPG carbon four components, with a diverse product range categorized into three main types: acetate esters, gasoline additives, and the succinic anhydride industry chain [7][23]. - The company has a significant market share in MTBE, becoming the largest exporter in China, and is expanding its production capacity to meet growing overseas demand [8][10]. Financial Performance - The company expects net profits for 2025-2027 to be -39 million, 402 million, and 760 million yuan, respectively, with corresponding PE ratios of 11.4X and 6.0X for 2026 and 2027 [10]. - In 2024, the company achieved a revenue of 7.701 billion yuan, a year-on-year increase of 16.51%, despite facing profit pressure due to consumption tax impacts on isooctane [43]. Research and Development - The company places a strong emphasis on R&D, with over 15% of its workforce dedicated to innovation. The management team consists of individuals with substantial technical expertise, which supports the company's focus on product upgrades and cost reduction through technological advancements [30][34].

Core Viewpoint - Yuxin Co., Ltd. is expected to report a net profit attributable to shareholders of the listed company for 2025 in the range of -50 million to -35 million yuan, indicating a significant year-on-year decrease of 117.37% to 124.32% in net profit excluding non-recurring gains and losses [1] Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders for 2025 to be between -50 million and -35 million yuan [1] - The expected net profit excluding non-recurring gains and losses is projected to be between -70 million and -50 million yuan, reflecting a year-on-year decline of 117.37% to 124.32% [1] Group 2: Reasons for Performance Change - The company's main products, including methyl tert-butyl ether, maleic anhydride, isopropanol, and butanone, are facing price pressure due to changes in industry supply and demand dynamics, leading to a narrowing price spread between products and raw materials [1] - The shutdown of the isooctane facility has also negatively impacted gross margins [1] - The subsidiary Boke New Materials' light hydrocarbon comprehensive utilization project faced challenges during trial production due to adverse weather and infrastructure issues, resulting in high material loss and switching costs [1] - Scheduled maintenance at subsidiaries Yuxin Chemical and Yuxin New Materials, along with a temporary shutdown due to a safety incident at Yuxin Chemical, affected production volumes [1] - The biodegradable materials market is currently in a downturn due to policy and demand factors, leading to the non-operation of Boke New Materials' PBAT production facility and the need for impairment provisions on related assets [1]

Core Insights - The financial misconduct of Ju Shi Chemical involves significant amounts, with inflated revenue of 157 million yuan, inflated costs of 158 million yuan, and a reduced profit of 1.66 million yuan, representing 8.32% of the total revenue for the period [2][8] Investigation Findings - The Guangdong Securities Regulatory Commission identified that the company manipulated its financial statements through various fictitious trading activities. The fraudulent transactions were conducted in three main ways: 1. The subsidiary Guan Zhen Technology controlled four trading companies to engage in fictitious trades without actual goods 2. The company intervened in third-party trade chains for polypropylene, relying solely on self-made transfer documents 3. The subsidiary Anhui Ju Run Trading Co., Ltd. sold goods to clients without actual shipment and later repurchased them at a markup, creating a cycle of fictitious transactions [3][9][11] Penalty Details - The Guangdong Securities Regulatory Commission proposed a total fine of 6.7 million yuan against Ju Shi Chemical and related responsible individuals. The company is required to rectify its practices and has been fined 2.4 million yuan. Specific penalties include: - 1.8 million yuan for the then Chairman and General Manager Chen Gang - 900,000 yuan for the then Director and Deputy General Manager Liu Penghui - 800,000 yuan for the then Director and Chief Financial Officer Wu Yang - 800,000 yuan for the then General Manager of Guan Zhen Technology Xu Jianjun - The penalties are based on violations of the Securities Law, indicating that the company failed to ensure the accuracy and truthfulness of the information disclosed in its 2023 semi-annual report [4][10]

Core Viewpoint - Guangdong Jushi Chemical Co., Ltd. (stock code: 688669) is facing administrative penalties for alleged securities fraud, specifically for false disclosures related to inflated revenues, costs, and profits through fictitious trade activities [1][4]. Summary by Relevant Sections Allegations and Findings - The Guangdong Securities Regulatory Bureau has identified that Jushi Chemical and its subsidiaries engaged in false trade activities to inflate financial figures. This includes controlling four trading companies to conduct non-existent trades and manipulating trade chains without commercial substance [4]. - The company reported inflated operating income of approximately 156.81 million yuan, inflated operating costs of about 158.47 million yuan, and a reduced profit of around 1.66 million yuan for the first half of 2023, representing 8.32%, 8.51%, and 6.81% of total revenue, costs, and profit respectively [4]. Penalties - The regulatory body plans to impose a fine of 2.4 million yuan on Jushi Chemical, along with warnings to the responsible personnel and additional fines [4]. Investor Compensation - Investors affected by the alleged fraud can file for compensation under the Supreme People's Court's judicial interpretation regarding false statements. This includes claims for losses incurred from the stock's price difference, commissions, and stamp duty [5]. - Investors who purchased Jushi Chemical shares between August 29, 2023, and November 21, 2025, and still hold them as of the latter date are eligible to seek compensation, subject to court validation [5].

Core Viewpoint - Guangdong Jushi Chemical Co., Ltd. (stock code: 688669) is facing administrative penalties for violations related to information disclosure, specifically for engaging in fictitious trade activities to inflate revenue, costs, and profits [2][6]. Group 1: Violations and Financial Impact - Jushi Chemical and its subsidiaries inflated revenue by CNY 156,807,377.35, costs by CNY 158,470,264.89, and reduced profits by CNY 1,662,887.54 in the first half of 2023, representing 8.32%, 8.51%, and 6.81% of total revenue, total costs, and total profit respectively [2][6]. - The company was found to have engaged in fictitious trade with four companies controlled by its subsidiary, Guangdong Guanzhen Technology Co., Ltd., involving transactions without actual goods [2][6]. Group 2: Regulatory Actions and Legal Implications - The China Securities Regulatory Commission (CSRC) Guangdong Bureau plans to issue a warning and impose fines on Jushi Chemical and its responsible personnel [2][6]. - Previous audits by Zhongxinghua Accounting Firm revealed four significant irregularities, leading to a warning from the CSRC [7]. - Investors affected by the company's actions can seek civil compensation for losses incurred due to the company's false statements, which may include investment differences, commissions, and stamp duties [7][8]. Group 3: Investor Compensation Process - A lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased Jushi Chemical's securities between August 29, 2023, and November 21, 2025, and who sold or continued to hold them after November 22, 2025 [8]. - Investors must provide specific documentation, including a copy of their ID, securities account information, and transaction records to register for compensation [9].

Core Viewpoint - The company, 聚石化学, is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for engaging in false disclosures and fraudulent trading practices, leading to potential claims from affected investors [1][2][3] Group 1: Regulatory Actions - 聚石化学 received an administrative penalty notice from the CSRC's Guangdong Regulatory Bureau on January 9, 2026, due to violations related to false statements [1] - The company and its subsidiaries were found to have inflated revenue, costs, and profits through fictitious trading activities [2][3] Group 2: Financial Impact - In the first half of 2023, 聚石化学 inflated its operating revenue by approximately 156.81 million yuan, operating costs by about 158.47 million yuan, and reduced profits by around 1.66 million yuan, which represented 8.32%, 8.51%, and 6.81% of total revenue, costs, and profit respectively [2][3] Group 3: Legal Recourse for Investors - Investors who purchased 聚石化学 stock between August 29, 2023, and November 22, 2025, and sold or continued to hold the stock after November 22, 2025, are eligible to initiate claims for compensation [2][3]